

Attorney's Docket No.: 11926-015001

1655
RECEIVED

JUL 11 2002

TECH CENTER 1600/290

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Vincent P. Stanton, Jr. Art Unit : 1655
Serial No. : 09/658,659 Examiner : A. Chakrabarti
Filed : September 8, 2000
Title : GENE SEQUENCE VARIANCE IN GENES RELATED TO FOLATE
METABOLISM HAVING UTILITY IN DETERMINING THE TREATMENT OF
DISEASE

Commissioner for Patents
Washington, D.C. 20231

COPY OF PAPERS
ORIGINALLY FILED

TRANSMITTAL LETTER

Correspondence relating to this application is enclosed. The required fees are computed below. Please apply any charges not covered, or any credits, to Deposit Account No. 06-1050.

Total Claims	32	-	16	=	16	\$144
Independent	4	-	3	=	1	\$42
First Presentation of Multiple Dependent Claims						\$140

Applicant hereby petitions under 37 C.F.R. §1.136 for a 0 month extension of time.

\$0


TOTAL FEE DUE

\$326

A check for \$326 is attached.

Respectfully submitted,

Date: 27 JUNE 2002


Anita L. Meiklejohn, Ph.D.
Reg. No. 35,283

Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20434110.doc


CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

June 27, 2002
Date of Deposit

Carrie A. Amonte
Signature

Carrie A. Amonte
Typed or Printed Name of Person Signing Certificate



Attorney's Docket No.: 11926-015001

22/0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Vincent P. Stanton, Jr. Art Unit : 1655
Serial No. : 09/658,659 Examiner : A. Chakrabarti
Filed : September 8, 2000
Title : GENE SEQUENCE VARIANCE IN GENES RELATED TO FOLATE
METABOLISM HAVING UTILITY IN DETERMINING THE TREATMENT OF
DISEASE

RECEIVED

JUL 11 2002

TECH CENTER 1600/2901

Commissioner for Patents
Washington, D.C. 20231

COPY OF PAPERS
ORIGINALLY FILED

RESPONSE

In response to the action mailed April 25, 2002, please amend the application as follows:

In the claims:

Cancel claims 171-181.

Add new claims 182-201 as follows.

Sub E2
DI
--182. An isolated nucleic acid probe comprising at least 15 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:15 (methylenetetrahydrofolate reductase), the probe comprising at least one of:

- (a) nucleotide 464 of SEQ ID NO:15 wherein N is G;
- (b) nucleotide 519 of SEQ ID NO:15 wherein N is T;
- (c) nucleotide 668 of SEQ ID NO:15 wherein N is T;
- (d) nucleotide 1059 of SEQ ID NO:15 wherein N is C;
- (e) nucleotide 1289 of SEQ ID NO:15 wherein N is A;
- (f) nucleotide 1308 of SEQ ID NO:15 wherein N is C; and

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

07/10/2002 AOSMAN1 00000089 09658659

01 FC:202
02 FC:203
03 FC:204

42.00 OP
144.00 OP
140.00 OP

Date of Deposit

June 27, 2002

Signature

Carrie A. Amonte

Carrie A. Amonte

Typed or Printed Name of Person Signing Certificate